A blood-based test has acceptable accuracy for colorectal cancer detection but not for advanced precancerous lesions in an ...

Let’s make June a turning point where more people get screened, more cancers are caught early and fewer lives are lost.

Fecal immunochemical testing (FIT) was more accurate than blood-based testing for detecting advanced precancerous colorectal ...

New blood tests can detect cancer recurrence earlier than traditional scans, potentially giving doctors and patients crucial information to make decisions about treatment. But more studies are needed ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 ...